Abstracts Archive - Page 1011 of 2607 - ACR Meeting Abstracts

Abstract Number: 1063 • 2019 ACR/ARP Annual Meeting
Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis
David Fox¹, Michael Whitfield ², Veronica Berrocal ³, Steven K. Lundy ⁴, Phillip Campbell ⁵, Stephanie Rasmussen ⁵, Ray Ohara ⁶, Alexander Stinson ⁶, Evan Wiewiora ⁷, Cathie Spino ⁷, Erica Bush ⁸, Daniel Furst ⁹, Shiv Pillai ¹⁰ and Dinesh Khanna ¹¹, ¹Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI, ²Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH, ³Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, ⁴TBD, Seattle, WA, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁶Washington University, St. Louis, MO, ⁷Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, ⁸Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁹University of California at Los Angeles, Los Angeles, CA, ¹⁰Ragon Institude of MGH, MIT and Harvard, Charlestown, MA, ¹¹Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor
Background/Purpose: Background: In a randomized controlled trial of abatacept in early diffuse systemic sclerosis (Khanna D, et al ACR 2018), we observed early clinical flares…
Abstract Number: 1064 • 2019 ACR/ARP Annual Meeting
CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy
Ross Lindsay¹, Janice Chen ¹, Robert Spiera ², Jessica Gordon ², Marie-Dominique Ah Kioon ³, Franck Barrat ³ and Christopher Brooks ¹, ¹Stemline Therapeutics, New York, ²Hospital for Special Surgery, New York, NY, ³HSS Research Institute, Hospital for Special Surgery, New York
Background/Purpose: Tagraxofusp is a novel targeted therapy directed to the interleukin-3 receptor (CD123). Tagraxofusp is comprised of human IL-3 recombinantly fused to a truncated diphtheria…
Abstract Number: 1065 • 2019 ACR/ARP Annual Meeting
Aberrant Expression Levels of Soluble Co-inhibitory Receptors Linked to Disease Activity in Systemic Sclerosis
Voon Ong¹, Svetlana Nihtyanova ², David Abraham ², Maithri Aspari ³, Christopher Denton ⁴ and Bent Deleuran ⁵, ¹UCL Medical School, Royal Free Campus, London, ²University College London, London, United Kingdom, ³Department of Biomedicine; Department of Rheumatology, Aarhus University, Arrhus, Denmark, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵Department of Biomedicine; Department of Rheumatology, Aarhus University, Aarhus, Denmark
Background/Purpose: Emerging evidence suggests dysregulated T cell activation in systemic sclerosis (SSc). Co-inhibitory-receptors such as TIM-3, PD-1 and LAG-3 are key factors in immune homeostasis…
Abstract Number: 1066 • 2019 ACR/ARP Annual Meeting
Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis
Christopher Denton ¹, Shiwen Xu ², Sue Verma ³ and Voon Ong⁴, ¹University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ²University College London, London, United Kingdom, ³Leadiant Biosciences, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London
Background/Purpose: Altered generation of adenosine from extracellular nucleotides by ectonucleotidases may orchestrate chronic injury responses and promote fibrosis via the adenosine A2A receptor (ADORA2A). We…
Abstract Number: 1067 • 2019 ACR/ARP Annual Meeting
Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis
Yiwei Yuan¹, Yue Wang ², Patricia Pioli ³ and Michael Whitfield ⁴, ¹Geisel School of Medicine at Dartmouth, Hanover, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth College, Hanover, ⁴Geisel School of Medicine at Dartmouth College, Biomedical Data Science at Dartmouth College, Hanover
Background/Purpose: Systemic sclerosis (SSc; scleroderma) is a rare, heterogenous autoimmune disease characterized by skin fibrosis, vasculopathy and internal organ involvement. SSc patients can be divided…
Abstract Number: 1068 • 2019 ACR/ARP Annual Meeting
Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures
Paula Ramos¹, Willian da Silveira ², Jena Wirth ¹, Nathan Wilson ¹, Robert Wilson ¹, Jin Hyun Nam ¹, E. Starr Hazard ¹, Jim Oates ³, Melissa Cunningham ¹, Dongjun Chung ¹ and Gary Hardiman ², ¹Medical University of South Carolina, Charleston, ²Queen’s University, Belfast, United Kingdom, ³Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder characterized by immune dysregulation, cutaneous and visceral fibrosis, and vasculopathy. It disproportionately affects African ancestry (AA)…
Abstract Number: 1069 • 2019 ACR/ARP Annual Meeting
CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis
Alisa Mueller¹, Andrea Fava ², Deepak Rao ¹ and Francesco Boin ³, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³UCSF, San Francisco, CA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by tissue fibrosis, vascular injury, and autoantibody production. CXCR5+ PD-1+ T follicular helper (Tfh) cells, which…
Abstract Number: 1070 • 2019 ACR/ARP Annual Meeting
Cytokine Signatures Differentiate Systemic Sclerosis Patients at High versus Low Risk for Pulmonary Arterial Hypertension
Kathleen Kolstad¹, Avani Khatri ², Michele Donato ³, Sarah Chang ⁴, Shufeng Li ⁵, Virginia Steen ⁶, Paul Utz ⁴, Purvesh Khatri ³ and Lorinda Chung ⁷, ¹Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, ²Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, ³Institute for Immunity, Transplantation and Infection, Stanford University, Palo Alto, ⁴Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, ⁵Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA, ⁶Georgetown University, Washington, D.C., USA, Georgetown, ⁷Stanford University, Palo Alto, CA
Background/Purpose: Pulmonary arterial hypertension (PAH) affects approximately 10% of patients with systemic sclerosis (SSc) and is a leading cause of death. Screening algorithms using clinical…
Abstract Number: 1071 • 2019 ACR/ARP Annual Meeting
A Common Transcriptional Signature Is Present in Circulating Classical Monocytes and Skin Macrophages in Systemic Sclerosis
Hadijat Makinde¹, Salina Dominguez ², Gaurav Gadhvi ³, Kathleen Aren ⁴, Chang Zeng ³, Garrett Eickelberg ³, Dinesh Khanna ⁵, Shervin Assassi ⁶, Tracy Frech ⁷, Monique Hinchcliff ⁸, Carla Cuda ⁹, Deborah Winter ² and Harris Perlman ², ¹Northwestern University, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, ³Northwestern University, Chicago, ⁴Northwestern.edu, Chicago, ⁵Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁸Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT, ⁹Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, IL
Background/Purpose: The etiology and pathogenesis of systemic sclerosis (SSc) are poorly understood; however, an increasing body of evidence supports an early inflammatory phase that precedes…
Abstract Number: 1072 • 2019 ACR/ARP Annual Meeting
CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis
Madhavi Latha Chalasani¹, Liyoung Kim ¹ and Theresa Lu ², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine (Microbiology and Immunology), New York
Background/Purpose: Monocytes and monocyte-derived cells play a crucial role during homeostasis and also during the development of various inflammatory diseases including skin fibrosis. Ly6Chi inflammatory…
Abstract Number: 1073 • 2019 ACR/ARP Annual Meeting
Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis
Angela Tam¹, Lauren Reinke-Breen ², Glenda Trujillo ², Shiwen Xu ¹, Christopher Denton ³, David Abraham ¹, Gabor Jarai ² and Voon Ong ⁴, ¹University College London, London, United Kingdom, ²Bristol-Myers Squibb, Pennington, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London
Background/Purpose: Chronic inflammation may modulate the balance of classical, intermediate and non-classical monocyte subsets (defined by CD14/CD16 expression)1. Monocytes are heterogeneous and subsets can be…
Abstract Number: 1074 • 2019 ACR/ARP Annual Meeting
Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells
Yongqing Wang ¹, nezam Altorok ² and Bashar Kahaleh², ¹University of Toeldo, TOLEDO, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Progressive functional and structural vascular disorder is one of the hallmark features of Systemic Sclerosis (Scleroderma, SSc). Vascular dysfunction lead to dysregulated vascular tone…
Abstract Number: 1075 • 2019 ACR/ARP Annual Meeting
The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases
Lena Sabih¹, Jennifer Strouse ¹, Nichole Nidey ², Gretchen Bandoli ³, Rebecca Baer ⁴, Sky Feuer ⁵, Laura Jelliffe-Pawlowski ⁵, Christina Chambers ⁶, Kelli Ryckman ² and Namrata Singh ⁷, ¹University of Iowa Hospitals and Clinics, Iowa City, ²UIOWA, Iowa City, ³University of California, San Diego, La Jolla, ⁴UCSD, La Jolla, ⁵UCSF, San Francisco, ⁶UCSD, San Diego, ⁷University of Iowa, Iowa City
Background/Purpose: Autoimmune rheumatic diseases (ARDs) are associated with adverse pregnancy outcomes (APOs). There are only a small number of studies that have looked at the…
Abstract Number: 1076 • 2019 ACR/ARP Annual Meeting
Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases
Christina Chambers¹, Yunjun Luo ², Diana L. Johnson ², Kenneth Lyons Jones ² and Ronghui Xu ², ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla
Background/Purpose: In infants whose mothers were treated with biologic therapies during pregnancy, there has been a theoretical concern regarding potential risk of infections. Several recent…
Abstract Number: 1077 • 2019 ACR/ARP Annual Meeting
Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications
Christina Chambers¹, Gretchen Bandoli ², Namrata Singh ³, Jennifer Strouse ⁴, Rebecca Baer ⁵, Brittney Donovan ⁶, Sky Feuer ⁷, Nichole Nidey ⁶, Kelli Ryckman ⁶ and Laura Jelliffe-Pawlowski ⁷, ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla, ³University of Iowa, Iowa City, ⁴University of Iowa Hospitals and Clinics, Iowa City, ⁵UCSD, La Jolla, ⁶UIOWA, Iowa City, ⁷UCSF, San Francisco
Background/Purpose: Autoimmune conditions are associated with an increased risk of adverse pregnancy complications and outcomes, suggesting that pregnancy complications may mediate the excess risk. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].